Differential effect of bortezomib on HLA class i and class II antibody

Transplantation

Volumn 98, Issue 6, 2014, Pages 660-665

  Philogene, Mary Carmelle ^a   Sikorski, Paul ^a   Montgomery, Robert A ^a   Leffell, Mary S ^a   Zachary, Andrea A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; HLA antibody; MHC molecules; Proteasome inhibition; Renal transplantation

Indexed keywords

BORTEZOMIB; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ANTIBODY; BORONIC ACID DERIVATIVE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BIOSYNTHESIS; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; IN VITRO STUDY; KIDNEY TRANSPLANTATION; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; APOPTOSIS; CELL MEMBRANE; DRUG EFFECTS; GRAFT REJECTION; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; LYMPHOCYTE; METABOLISM; RETROSPECTIVE STUDY;

ANTIBODIES; APOPTOSIS; BORONIC ACIDS; CELL MEMBRANE; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MALE; PROTEASOME INHIBITORS; PYRAZINES; RETROSPECTIVE STUDIES;

EID: 84922480547     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000132     Document Type: Article

References (30)

1. Terasaki PI. A personal perspective: 100-year history of the humoral theory of transplantation. Transplantation 2012; 93: 751.
2. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant 2013; 13 Suppl 1: 11.
3. DiLillo DJ, Hamaguchi Y, Ueda Y, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008; 180: 361.
4. Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibodysecreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008; 8: 133.
5. Laubach JP, Mitsiades CS, Mahindra A, et al. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw 2009; 7: 947.
6. Everly MJ. A summary of bortezomib use in transplantation across 29 centers. Clin Transpl 2009: 323.
7. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
8. Kute VB, Vanikar AV, Trivedi HL, et al. Desensitization protocol for highly sensitized renal transplant patients: a single-center experience. Saudi J Kidney Dis Transpl 2011; 22: 662.
9. Tzvetanov I, Spaggiari M, Joseph J, et al. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature. Transplant Proc 2012; 44: 2971.
10. Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486.
11. Wahrmann M, Haidinger M, Kormoczi GF, et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89: 1385.
12. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
13. Ryckewaert A, Allain-Launay E, Moreau A, et al. Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient. Pediatr Transplant 2013; 17: E131.
14. Kannabhiran D, Everly MJ, Walker-McDermott JK, et al. Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection. Clin Transpl 2012: 229.
15. Khuu T, Cadeiras M, Wisniewski N, et al. k, A. Reduced HLA Class II antibody response to proteasome inhibition. J Heart Lung Transplant 2013; 32: S114.
16. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
17. Craiu A, Gaczynska M, Akopian T, et al. Lactacystin and clasto- Lactacystin beta-Lactone modify multiple proteasome beta-subunits and inhibits intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem1997; 272: 13437.
18. Voorhees PM, Dees EC, O'Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9: 6316.
19. Reece DE, Sullivan D, Lonial S, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol 2011; 67: 57.
20. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993.
21. Sijpkens YW, Doxiadis II, Mallat MJ, et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2003; 75: 204.
22. Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibodymediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011; 91: 1218.
23. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783.
24. Hughes EA,Hammond C, Cresswell P.Misfoldedmajor histocompatibility complex class i heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proc Natl Acad Sci U S A 1997; 94: 1896.
25. Georgopoulos NT, Proffitt JL, Blair GE. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 2000; 19: 4930.
26. Loch S, Tampe R. Viral evasion of the MHC class I antigen-processing machinery. Pflugers Arch 2005; 451: 409.
27. Marcilla M, Cragnolini JJ, Lopez de Castro JA. Proteasome-independent HLA-B27 ligands arise mainly from small basic proteins. Mol Cell Proteomics 2007; 6: 923.
28. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76: 1519.
29. Zachary AA,Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364.
30. Zachary AA, Lucas DP, Detrick B, et al. Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution. Hum Immunol 2009; 70: 496